News - Dermatologicals

Filter

Current filters:

Dermatologicals

Popular Filters

28 to 52 of 117 results

Abraaj sells stake in Opalia Pharma to Recordati

05-11-2013

The Dubai-based Abraaj Group, an investor operating in global growth markets, has announced its full…

Abraaj GroupDermatologicalsGastro-intestinalsGenericsMergers & AcquisitionsOpalia PharmaRecordatiRespiratory and PulmonaryRest of the World

Rigel sees clear forward path for fostamatinib but will drop R333

25-10-2013

Clinical-stage US drug developer Rigel Pharmaceuticals has announced mixed updates on two of its pipeline…

BiotechnologyDermatologicalsfostamatinibImmunologicalsR333RegulationResearchRigel Pharmaceuticals

High hopes for Cellceutix’ Brilacidin for serious skin infections

14-10-2013

US clinical-stage biopharmaceutical company Cellceutix says that it is completing the required documentation…

Antibiotics and Infectious diseasesbrilacidinCellceutixDermatologicalsPharmaceuticalResearch

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

09-10-2013

Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the…

DermatologicalsNorth AmericaPfizerPharmaceuticalResearchtofacitinibXeljanz

Novartis reports further progress with its psoriasis candidate secukinumab

Novartis reports further progress with its psoriasis candidate secukinumab

08-10-2013

Novartis recently announced results from the head-to-head Phase III FIXTURE study showing secukinumab…

DermatologicalsNovartisPharmaceuticalResearchsecukinumab

Novartis presents strong new Ph III results with omalizumab in CSU

Novartis presents strong new Ph III results with omalizumab in CSU

05-10-2013

Novartis has presented new results from the Phase III ASTERIA I study showing omalizumab was effective…

DermatologicalsGenentechNovartisOmalizumabPharmaceuticalResearchXolair

Astellas’ antifungal study reports positive results

30-09-2013

Astellas Pharma has announced positive topline data from the Phase III invasive aspergillosis study (SECURE)…

Asia-PacificAstellas PharmaBasilea PharmaceuticaDermatologicalsisavuconazolePharmaceuticalResearch

Singapore to launch collaborative program into skin research

27-09-2013

Singapore is committing close to S$100 million ($79.6 million) to skin research, announced the Skin Research…

Asia-PacificDermatologicalsPharmaceuticalResearch

LEO Pharma reports positive Phase III data for ingenol mebutate gel in actinic keratosis

26-09-2013

Privately-held Danish dermatology specialist LEO Pharma has announced the completion of a Phase III study…

DermatologicalsEuropeingenol mebutate gelLEO PharmaPharmaceuticalResearch

KYTHERA submental fat drug candidate meets all primary endpoints in Ph III

17-09-2013

US biotech firm KYTHERA Biopharmaceuticals (Nasdaq: KYTH) saw its stock upgraded to $50 a share from…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsPharmaceuticalResearch

ICAAC: Positive preliminary results of new luliconazole formulation in onychymycosis trial

16-09-2013

Luliconazole, a medication approved in Japan for the treatment of superficial mycosis in a 1% formulation,…

DermatologicalsLuliconazoleNihon NohyakuNorth AmericaPharmaceuticalResearch

Karo Bio gets first milestone in Pfizer collaboration

06-09-2013

Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Rigel Pharma to focus on three leading clinical programs

05-09-2013

USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) today announced its plans to focus the company's resources…

DermatologicalsfostamatinibManagementOphthalmicsPharmaceuticalR333R348ResearchRigel Pharmaceuticals

Onglyza meets primary safety endpoint in SAVOR CV outcomes trial

02-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: MBY) today…

AstraZenecaBristol-Myers SquibbCardio-vascularDermatologicalsOnglyzaPharmaceuticalResearch

NovaBiotics enters co-development agreement for Novexatin

28-08-2013

Scotland-headquartered clinical-stage biotech firm NovaBiotics has entered into an exclusive agreement…

BiotechnologyDermatologicalsLicensingNovaBioticsNovexatinTaro Pharmaceuticals

Galderma drug is first FDA-approved facial erythema of rosacea treatment

27-08-2013

Switzerland-headquartered Galderma Laboratories says that the US Food and Drug Administration has approved…

brimonidineDermatologicalsGaldermaMirvasoNorth AmericaPharmaceuticalRegulation

Actelion bid for Ceptaris looks secured as FDA approves Valchlor

26-08-2013

Privately-held USA-based Ceptaris Therapeutics revealed yesterday (August 26) that the US Food and Drug…

ActelionBiotechnologyCeptaris TherapeuticsDermatologicalsMergers & AcquisitionsNorth AmericaRegulationValchlor

First in class novel biologic for psoriasis launched in India

13-08-2013

Bangalore, India-based Biocon (BSE: 532523), Asia's premier biotechnology company, has launched its 'first…

ALZUMAbAsia-PacificBioconBiotechnologyDermatologicalsitolizumabMarkets & Marketing

Mayne Pharma signs up deals to market Subacap in Europe

12-08-2013

Australian drugmaker Mayne Pharma (ASX: MYX) says it has signed two marketing and distribution agreements…

DermatologicalsEuropeGlenmark PharmaceuticalsIsdinitraconazoleLicensingMarkets & MarketingMayne PharmaPharmaceuticalSubacap

EMA suspends use of oral ketoconazole because of liver injury risk

26-07-2013

The European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) has recommended…

DermatologicalsEuropeKetoconazolePharmaceuticalRegulation

Galen in upfront $4.5million deal with Novo Research for US rights for Synera pain relief patch

11-07-2013

Canada's Nuvo Research (TSX: NRI) today (July 11) announced that its wholly owned subsidiary, ZARS Pharma,…

DermatologicalsGalen USLicensingNorth AmericaNuvo ResearchPharmaceuticalSyneraZARS Pharma

Novartis' secukinumab demonstrates superiority to rival Enbrel in psoriasis study

08-07-2013

Swiss drug major Novartis (NOVN: VX) has announced results from a Phase III psoriasis study which showed…

AbbVieAmgenDermatologicalsEnbrelHumiraJanssen BiotechNovartisPharmaceuticalsecukinumabStelara Injectiontofacitinib

Swedish Pergamum reports positive preliminary efficacy results of LL-37 in chronic leg ulcers

05-07-2013

Pergamum, a portfolio company of Sweden-based investment company Karolinska Development, says that the…

BiotechnologyDermatologicalsKarolinska DevelopmentResearch

28 to 52 of 117 results

Back to top